Xenon Pharmaceuticals Inc
XENE
Market Cap$3.21B
Close$
$2.06
94.9% downside
Current Fair Value
94.9% downsideOvervalued by 94.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.21 Billion |
|---|---|
| Enterprise Value | $2.68 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.5 |
| Beta | 0.65 |
| Outstanding Shares | 75,463,489 |
| Avg 30 Day Volume | 333,214 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -19.55 |
|---|---|
| PEG | -37.36 |
| Price to Sales | - |
| Price to Book Ratio | 5.07 |
| Enterprise Value to Revenue | 20290.53 |
| Enterprise Value to EBIT | -14.39 |
| Enterprise Value to Net Income | -17 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
ESG Score
No data
About Xenon Pharmaceuticals Inc
CEO: Simon Pimstone